Have a feature idea you'd love to see implemented?
Let us know!
NAUT Nautilus Biotechnology Inc
Price (delayed)
$2.78
Market cap
$348.64M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.56
Enterprise value
$356.36M
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics
Highlights
Nautilus Biotechnology's debt has decreased by 11% YoY and by 3% QoQ
NAUT's EPS is down by 22% year-on-year
Nautilus Biotechnology's net income has decreased by 20% YoY and by 3.3% QoQ
Key stats
What are the main financial stats of NAUT
Market
Valuations
Earnings
Shares outstanding
125.41M
Market cap
$348.64M
Enterprise value
$356.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$69.64M
EBITDA
-$63.38M
Free cash flow
-$59.81M
Per share
Balance sheet
Liquidity
EPS
-$0.56
Free cash flow per share
-$0.48
Book value per share
$1.88
Revenue per share
$0
TBVPS
$2.18
Total assets
$272.75M
Total liabilities
$37.47M
Debt
$32.6M
Equity
$235.28M
Working capital
$162.25M
Debt to equity
0.14
Current ratio
19.69
Quick ratio
19.29
Net debt/EBITDA
-0.12
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-23.5%
Return on equity
-27.1%
Return on invested capital
-24.4%
Return on capital employed
-26.4%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NAUT stock price
How has the Nautilus Biotechnology stock price performed over time
Intraday
0.36%
1 week
-2.11%
1 month
-9.74%
1 year
18.3%
YTD
-7.02%
QTD
-2.46%
Financial performance
How have Nautilus Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$81.47M
Net income
-$69.64M
Gross margin
N/A
Net margin
N/A
Nautilus Biotechnology's net income has decreased by 20% YoY and by 3.3% QoQ
Nautilus Biotechnology's operating income has decreased by 18% YoY and by 2.2% from the previous quarter
Growth
What is Nautilus Biotechnology's growth rate over time
Valuation
What is Nautilus Biotechnology stock price valuation
P/E
N/A
P/B
1.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NAUT's EPS is down by 22% year-on-year
The equity has decreased by 19% YoY and by 6% from the previous quarter
The stock's price to book (P/B) is 5% more than its last 4 quarters average of 1.4
Efficiency
How efficient is Nautilus Biotechnology business performance
The return on equity has declined by 43% year-on-year and by 9% since the previous quarter
NAUT's return on assets is down by 40% year-on-year and by 8% since the previous quarter
The ROIC is down by 7% year-on-year and by 4.7% since the previous quarter
Dividends
What is NAUT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NAUT.
Financial health
How did Nautilus Biotechnology financials performed over time
Nautilus Biotechnology's total assets has decreased by 18% YoY and by 6% from the previous quarter
NAUT's total liabilities is down by 9% year-on-year and by 4.3% since the previous quarter
Nautilus Biotechnology's debt is 86% lower than its equity
The equity has decreased by 19% YoY and by 6% from the previous quarter
Nautilus Biotechnology's debt has decreased by 11% YoY and by 3% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.